Proton pump inhibitors (PPIs) are commonly used to reduce stomach acid production and treat conditions such as gastroesophageal reflux disease (GERD) and ulcers. Commonly prescribed PPIs include omeprazole (Prilosec), pantoprazole (Protonix), esomeprazole (Nexium), and dexlansoprazole (Dexilant).
There has been some concern regarding their potential impact on bone health, particularly in relation to osteoporosis.
Reduced Calcium Absorption: PPIs may reduce the absorption of calcium, particularly calcium carbonate, which requires an acidic environment for optimal absorption. This could lead to decreased calcium levels in the body, potentially increasing the risk of osteoporosis over time.
Magnesium Levels: Long-term use of PPIs may lead to low magnesium levels, which are also important for bone health. Hypomagnesemia can contribute to bone mineral density loss and increase the risk of fractures.
Potential for Increased Fracture Risk: Some studies have suggested an association between long-term PPI use and an increased risk of fractures, particularly hip, wrist, and spine fractures. This may be linked to decreased bone mineral density associated with calcium and magnesium absorption issues.
Recommendations:
Considerations for Patients also Struggling with Gastroparesis:
Click Here to Learn More